Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H8N2S |
| Molecular Weight | 176.238 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(=CS1)C2=CC=CC=C2
InChI
InChIKey=PYSJLPAOBIGQPK-UHFFFAOYSA-N
InChI=1S/C9H8N2S/c10-9-11-8(6-12-9)7-4-2-1-3-5-7/h1-6H,(H2,10,11)
| Molecular Formula | C9H8N2S |
| Molecular Weight | 176.238 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6970807
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6970807
Phenthiazamine was developed by Sekizawa et al. as a centrally acting anesthetic for fish. The time required to reduce the positive ganglionic potential in the sympathetic ganglion by phenthiazamine was prolonged in the presence of higher concentrations of Ca2+. The Ca2+-dependent action potential of guinea-pig ureter was reduced by this compound, whereas it did not affect the Na+-dependent action potential.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6970807
Curator's Comment: CNS active in fish and frog
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6970807
Curator's Comment: Phenthiazamine was developed by Sekizawa et al. as a centrally acting anesthetic for fish.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0005262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6970807 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6970807 |
Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Synthesis, physico-chemical investigations of Co(II), Ni(II) and Cu(II) complexes and their in vitro microbial, cytotoxic, DNA cleavage studies. | 2010-06 |
|
| 4-Hex-yloxy-3-methoxy-benzaldehyde. | 2009-05-14 |
|
| Synthesis and Antibacterial Assessment of N-[4-(4-substituted phenyl)-1,3-thiazol-2-yl]-1,3,5-triazin-2-amine. | 2009-01 |
|
| 5-Methyl-2-[3-(4-phenylthiazol-2-yl)triazenyl]benzenesulfonic acid as a chromogenic reagent of N-cetylpyridinium chloride Synthesis, mechanism and analytical application. | 2008-01-15 |
|
| Synthesis of a novel bistriazene reagent 4,4'-bis[3-(4-phenylthiazol-2-yl)triazenyl]biphenyl and its highly sensitive color reaction with mercury(II). | 2007-04-30 |
|
| Synthesis, anti-inflammatory and analgesic activities evaluation of some mono, bi and tricyclic pyrimidine derivatives. | 2005-11-15 |
|
| Complexes of ruthenium(III) with some 2-aminothiazole derivatives/synthesis, properties and pharmacological studies. | 2004 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6970807
Increase in the amplitude of the slow P potential was found in all the specimens of Frog sympathetic ganglion with Phenthiazamine at 0.5 mM
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:51:27 GMT 2025
by
admin
on
Mon Mar 31 21:51:27 GMT 2025
|
| Record UNII |
WF2822RIUS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2010-06-2
Created by
admin on Mon Mar 31 21:51:27 GMT 2025 , Edited by admin on Mon Mar 31 21:51:27 GMT 2025
|
PRIMARY | |||
|
2528
Created by
admin on Mon Mar 31 21:51:27 GMT 2025 , Edited by admin on Mon Mar 31 21:51:27 GMT 2025
|
PRIMARY | |||
|
40302
Created by
admin on Mon Mar 31 21:51:27 GMT 2025 , Edited by admin on Mon Mar 31 21:51:27 GMT 2025
|
PRIMARY | |||
|
WF2822RIUS
Created by
admin on Mon Mar 31 21:51:27 GMT 2025 , Edited by admin on Mon Mar 31 21:51:27 GMT 2025
|
PRIMARY | |||
|
DTXSID4043804
Created by
admin on Mon Mar 31 21:51:27 GMT 2025 , Edited by admin on Mon Mar 31 21:51:27 GMT 2025
|
PRIMARY | |||
|
217-926-8
Created by
admin on Mon Mar 31 21:51:27 GMT 2025 , Edited by admin on Mon Mar 31 21:51:27 GMT 2025
|
PRIMARY |